SUPERNUS PHARMACEUTICALS, INC. (SUPN) scores 48 out of 100 on boothcheck's 11-model valuation framework. Verdict: Poor The estimated fair value is 12.04, representing a 77% premium to fair value. Quantitative score: 49/100. Qualitative score: 70/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.